AcelRx Pharmaceuticals’ programs to feature at upcoming annual meeting

Download PDF Copy

Oct 15 2009

NewsGuard 100/100 Score

AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab(TM) formulation of sufentanil will be featured in two oral presentations at the upcoming American Society of Anesthesiologists Annual Meeting in New Orleans.

Dr. Pamela Palmer, Chief Medical Officer of AcelRx, will present in the following sessions. Abstracts are available through the American Society of Anesthesiologists web site.

Tuesday, October 20, 2009 Oral Session - Chronic & Cancer Pain 8:00 am, Room 355 Abstract 1040 "Pharmacokinetics and Dose Proportionality of Sublingual Sufentanil NanoTab in Healthy Volunteers" Tuesday, October 20, 2009 Oral Session - Regional Anesthesia & Acute Pain 1:00 pm, Room 355 Abstract 1222 "Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers"

Source:

AcelRx Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Tags: Acute Pain, Cancer, Chronic, Pain, Pharmaceuticals, Pharmacokinetics

Comments (0)

Download PDF Copy

Suggested Reading

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years